Navigation Links
Electrosurgery Ensures Integrity Of Cochlear Implant Following Adenoids Removal

Electrosurgery employed in the removal of tonsils and adenoids does not result in a compromise of the integrity of the cochlear implant device//, a new study has found. The findings of the present study could eventually pave way for a safe, maximal pain-free and effective method to remove tonsils and adenoids in deaf children.

Cochlear implant (CI) recipients have been discouraged from having monopolar electrosurgery for ear, nose, and throat procedures due to concerns over possible damage to the implant and the auditory neurons. While monopolar electrosurgery is rarely, if ever, absolutely necessary, it greatly facilitates treatment in certain procedures such as adenoidectomy. With a growing population of patients receiving CIs at very young ages, more children with CIs may subsequently develop a need for an adenoidectomy, such as obstructive sleep apnea. Unfortunately, no published studies have evaluated the safety of electrosurgical adenoidectomy in CI reipients.

Over the past few years, radiofrequency bipolar electrosurgery (eg, Coblation?) has become popular for adenoidectomy and tonsillectomy because of reports of less post-tonsillectomy pain. The reduction in post-tonsillectomy pain has been attributed to the more limited spread of electrical current and reduced tissue temperatures with Coblation bipolar electrosurgery relative to monopolar electrosurgery. The more limited current spread with Coblation electrosurgery would theoretically impart less risk to a CI and the auditory neurons. As with other electrosurgical techniques, no studies have reported the safety of Coblation adenoidectomy in CI recipients.

Twelve frozen 40 – 50 pound pigs and 12 cochlear implants with superficial defects were used for the experiment. After thawing the pigs, the cochlear implants were placed unilaterally via a standard transmastoid approach. Saline was infiltrated into the cochlea and middle ear to ensure contact between the electrode and surro unding tissues, then the wound was closed with running locked silk suture.

Nasopharyngeal Electrosurgery: The palate and posterior wall of the nasopharynx were treated with either monopolar electrocoagulation or Coblation bipolar electrosurgery. Both were applied with continuous saline irrigation to ensure maximum electrical conduction. The monopolar cautery unit was set at 50, which is double the energy level typically used for adenoidectomy at our institution, and applied for 15 minutes; radiofrequency bipolar electrosurgery was performed using the Coblator II system. The duration of Coblation treatment was doubled to 30 minutes because of the inability to double the intensity of treatment beyond its maximum level of 9, as was done with the monopolar electrosurgical treatment. This yielded a total of 270 J with Coblation treatment.

Cochlear Implant Integrity Assessment: Implants underwent standard integrity checks by the manufacturer prior to shipping and after electrosurgery. These evaluations included open circuits, device electronics, ability of the device to function at normal levels, and stability of stimulation delivered by each channel. The manufacturers were blinded to the treatment group. Immediately prior to and after subjecting the animals to electrosurgery, ‘clinical’ telemetry was performed on each device by the respective manufacturer’s technical staff to ensure proper functioning of the device in situ.

Intraoperative telemetry revealed normal impedances and device integrity in all of the cochlear implants with the exception of the fifth Nucleus 24 CI, treated with electrocautery, which demonstrated an open electrode #15, both pre and post electrosurgery. Manufacturer testing revealed no additional abnormalities in any of the cochlear implants exposed to either monopolar or Coblation electrosurgery.

Conclusions: The study findings were intended to evaluate the cochlear implant device integrity, not support the safety of monopolar or Coblation electrosurgery in respect to the patient. The study also did not evaluate the effects of either treatment modality on auditory neurons. Further evaluation of adenoid electrosurgery would require evaluation of electrically evoked auditory brainstem response testing in a long-term animal model, and ultimately in human CI recipients.

The researchers believe that their observations should be viewed as merely a first step toward establishing the safety of various electrosurgical technologies for head and neck procedures, such as adenoidectomy, and they should be recognized as not being necessarily directly reflective of the human condition. They suggest that in the absence of definitive high level evidence (i.e., controlled trials) to guide treatment decisions, lower level evidence must be used to guide treatment. On a theoretical level, Coblation should be safer than monopolar electrosurgery, because the former involves bipolar current passing through tightly approximated electrodes on the end of the electrosurgical wand, whereas monopolar current may spread in a much more diffuse pattern from the nasopharynx to the grounding pad. Unlike other forms of electrosurgery, there are no reports on the safety of Coblation electrosurgery with other implantable stimulators, such as pacemakers and cardiac defibrillators.

Source: Newswis
'"/>




Related medicine news :

1. Voluntary Error-Reporting System Ensures Patient Safety
2. Watchful Eyes Ensures Honesty
3. Beauty Queens Urge On The Importance Of Maintaining Bone Integrity
4. Yeast Genome Unravels Genes Critical For Maintaining DNA Integrity
5. Cell Survival Depends on Chromosome Integrity
6. Early Cochlear Implants Prove To Be Effective
7. Earlier the Cochlear Implants Used Better the Speech
8. Cochlear Implants in Both Ears Enables Better Hearing
9. Making Sense of the World Through a Cochlear Implant
10. Cochlear Implantation Increases Meningitis Risk
11. Implantable Contact Lens Found Safe and Effective
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing ... a new CEO. , Bright Pink is proud to announce Katie Thiede as their ... to a new role as Chairman of the Board and launched a national search ...
(Date:4/24/2017)... ... , ... The John P. McGovern Museum of Health and Medical Science is ... cognitive health, and share results with their physicians. Members and guests can sign up ... , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a new ... a day, Quick Care provides patients with the option to request and begin ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: